You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

From High-Risk Dyslipidemia to CV Disease: It's Time to Improve Management

Authors: Khung Keong Yeo, MBBS; Junya Ako, MD; David K. L. Quek, MBBS, FRCP, FESC, FACC; Tan Ru San, MBBS, MRCPFaculty and Disclosures


Posted: 11/9/2017

This educational activity is intended for an international audience of Asia-Pacific healthcare professionals, specifically cardiologists, diabetologists, endocrinologists, and primary care physicians involved in the management of patients with high-risk dyslipidemia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of dyslipidemia on cardiovascular (CV) events
    • Latest clinical data on new lipid-lowering therapies, including proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, in patients with high-risk dyslipidemia, and particularly, familial hypercholesterolemia
  • Have greater competence related to
    • The interpretation of statistics in clinical trials

Contents of This Activity

New Available Therapeutic Data in High-Risk Dyslipidemia

Dr Yeo presents recent data on lipid-lowering therapy in patients with high-risk dyslipidemia.
Khung Keong Yeo, MBBS

Atherosclerosis and High-Risk Dyslipidemia: Disease Burden in Asia Pacific and Unmet Needs

Dr Ako presents epidemiological data on CV events and dyslipidemia in Asia and identifies unmet needs.
Junya Ako, MD

Why Is It Important to Screen Asian Patients and to Reduce LDL Cholesterol?

Dr Quek presents the effects of hypercholesterolemia on CV events and LDL-C targets in different populations.
David K. L. Quek, MBBS, FRCP, FESC, FACC

Interpreting Statistics in Outcome Trials

Dr Ru San explains the importance of outcome trials and their interpretation.
Tan Ru San, MBBS, MRCP
  • Print